Coultreon Biopharma
PVT · PVT·Leuven, Belgium·Private·Phase 1
Clinical-stage biotech developing oral SIK3 inhibitors for autoimmune and inflammatory diseases. Lead asset COL-5671, acquired from Galapagos, acts like a combination anti-TNF-alpha/anti-IL-23 therapy in a single pill. Raised $125M in Series A in April 2026 backed by Sofinnova, Forbion, Novo Holdings, and Regeneron Ventures.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Coultreon Biopharma website | Website | May 5, 2026 | 2 |